Fosun Pharma unit gets drug application accepted

Shanghai Fosun Pharmaceutical Group announced that its subsidiary Shanghai Chaohui Pharmaceutical received acceptance from the National Medical Products Administration for its Polyethylene Glycol Electrolyte Powder Compound drug registration application.

The chemical drug is intended for bowel preparation prior to colonoscopy, barium enema X-ray imaging, and colorectal surgery.

Fosun Pharma and its subsidiaries have invested approximately RMB 4.74 million in research and development of the compound series. According to IQVIA CHPA data, sales of the compound in mainland China reached approximately RMB 307 million in 2024.

The company said the application acceptance will not significantly impact current performance.